Cargando…

VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience

Background: Complete response (CR) and very good partial response (VGPR) are targeted with pre-ASCT induction regimens in patients by diagnosed multiple myeloma (MM), who are candidates for ASCT. In this study, it was aimed to compare the response and survival evaluations of cases who underwent indu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yıkılmaz, Aysun Şentürk, Akinci, Sema, Bakanay, Şule Mine, Dilek, İmdat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876426/ https://www.ncbi.nlm.nih.gov/pubmed/33603986 http://dx.doi.org/10.18502/ijhoscr.v14i4.4481

Ejemplares similares

Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera
por: Yikilmaz, Aysun Şentürk, et al.
Publicado: (2020)

Thiol-disulphide Homeostasis in Essential Thrombocythemia Patients
por: Yıkılmaz, Aysun Şentürk, et al.
Publicado: (2019)

Prognostic Value of the Expression of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) in Chronic Lymphocytic Leukemia
por: Yikilmaz, Aysun Şentürk, et al.
Publicado: (2023)

VAD chemotherapy as remission induction for multiple myeloma.
por: Anderson, H., et al.
Publicado: (1995)

Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels
por: Ceran, Funda, et al.
Publicado: (2022)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
por: Huwyler, Fabrizio, et al.
Publicado: (2023)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

A Rare Lymphoproliferative Disease: Castleman Disease
por: Gündüz, Eren, et al.
Publicado: (2021)

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?
por: Bakanay, Sule Mine, et al.
Publicado: (2012)

Is there a role for ‘modified VAD’ in the treatment of multiple myeloma?
por: Agazzi, A, et al.
Publicado: (2009)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
por: Güney, Tekin, et al.
Publicado: (2022)

The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis
por: He, Gan-Lin, et al.
Publicado: (2018)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
por: Kropff, Martin, et al.
Publicado: (2009)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

(333) Transitioning Vad Care: Outcomes of Virtual Vad Follow Up Visits
por: Meehan, K., et al.
Publicado: (2023)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
por: Ataca Atilla, Pınar, et al.
Publicado: (2019)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

Work for the V.A.D.s.
Publicado: (1919)

The Victimisation of V.A.D.s.
por: Green, J. E.
Publicado: (1919)

Editorial: Hemostasis in ECMO and VAD
por: Teruya, Jun, et al.
Publicado: (2019)

The Victimisation of V.A.D.s.
Publicado: (1919)

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

PB1992: HISPANIC ETHNICITY AS A STRONG PREDICTOR OF POOR RESPONSE TO INDUCTION THERAPY AND ASCT IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Chineke, I., et al.
Publicado: (2022)

Learning From Failure: Negative Trials in Oncology
por: Nardo, Mirella, et al.
Publicado: (2023)

Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids
por: Pavan, M., et al.
Publicado: (2010)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

The Control of V.A.D. Hospitals
Publicado: (1918)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t1349mkt68547safdte7lbkrub